Vera Therapeutics Inc (VERA) - Total Assets
Based on the latest financial reports, Vera Therapeutics Inc (VERA) holds total assets worth $621.74 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Vera Therapeutics Inc (VERA) net asset quality to measure how much of total assets are equity-financed.
Vera Therapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Vera Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Explore VERA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Vera Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vera Therapeutics Inc's total assets of $621.74 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.3% |
| Accounts Receivable | $3.29 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Vera Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Vera Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vera Therapeutics Inc's current assets represent 99.2% of total assets in 2025, an increase from 66.3% in 2019.
- Cash Position: Cash and equivalents constituted 48.3% of total assets in 2025, down from 59.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Vera Therapeutics Inc Competitors by Total Assets
Key competitors of Vera Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Vera Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.64 | 27.68 | 25.42 |
| Quick Ratio | 13.64 | 27.68 | 25.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $570.65 Million | $584.18 Million | $92.11 Million |
Vera Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Vera Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.21 |
| Latest Market Cap to Assets Ratio | 3.42 |
| Asset Growth Rate (YoY) | 12.1% |
| Total Assets | $734.73 Million |
| Market Capitalization | $2.51 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Vera Therapeutics Inc's assets at a significant premium (3.42x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vera Therapeutics Inc's assets grew by 12.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vera Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Vera Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $734.73 Million | +12.06% |
| 2024-12-31 | $655.68 Million | +273.51% |
| 2023-12-31 | $175.55 Million | +33.56% |
| 2022-12-31 | $131.44 Million | +56.94% |
| 2021-12-31 | $83.75 Million | +53.51% |
| 2020-12-31 | $54.55 Million | +913.83% |
| 2019-12-31 | $5.38 Million | -- |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous in… Read more